Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc.

CGEM·NASDAQ

$15.21

-0.85%
HealthcareMedical - Pharmaceuticals

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

At a Glance

Live Snapshot
Market Cap$934.78M
EPS-3.7200
P/E Ratio-4.09
Earnings Date08/06/2026

cgem

Net Income

Last Annual Value

-219.88M

3-Year CAGR

-44%

5-Year CAGR

-34%

10-Year CAGR

-32%

Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Competitors Analysis of Net Income

CGEM · NASDAQ
CompanyNet Income
CAGR 3Y
CAGR 5Y
CAGR 10Y
-219.88M
N/AN/AN/A 
-70.30M
N/AN/AN/A
CBLL logo
CeriBell, Inc.
NASDAQ:CBLL
-53.41M
N/AN/AN/A
EHAB logo
Enhabit, Inc.
NYSE:EHAB
-4.60M
N/AN/AN/A
-74.90M
N/AN/AN/A
-236.93M
N/AN/AN/A
-129.87M
N/AN/AN/A
-3.35M
N/AN/AN/A
Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Fair Value Envelope

CGEM · NASDAQ

Our analysis suggests that CGEM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $15.21, this represents a potential HIDDEN relative to our calculated worth for Cullinan Therapeutics, Inc..

Intrinsic Value
Current Price: $15.21